Standardization of a New Psychophysical Olfactory Test, TODA2

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06386523

Acronym

TODA-STAR

Enrollment

112

Registered

2024-04-26

Start date

2024-10-21

Completion date

2025-03-25

Last updated

2025-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients Without an Olfactory Disorder

Brief summary

Recruitment of patients consulting the IUFC for another pathology unrelated to an olfactory disorder: Interview and clinical examination and Passing the 2 olfactory tests for 30 voluntary's patients, a second consultation of 15 minutes including the time of the test within 7 days after the 1st

Detailed description

Recruitment of patients consulting the IUFC for another pathology unrelated to an olfactory disorder (otosclerosis, pre- surgery, tonsillectomy, cosmetic surgery) Data collection methods: 2 parts (duration approximately 1.5 hours) and for 30 volunteer patients, a second consultation of 15 minutes including the time of the test within 7 days after the 1st: 1. Interview and clinical examination 2. Passage of olfactory tests: TODA2 and Sniffin Stick Test in unirhinal 3. On a voluntary basis, and within a limit of 30 patients, those who agree to come back a second time will be able to benefit from a second pass of the TODA2 on Day 7.

Interventions

DIAGNOSTIC_TESTPassage of olfactory tests

test TODA2 and Sniffin Stick Test

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Subjects \> 18 years old * No olfactory complaints; subjective estimation of normal olfaction * Affiliated to the Social Security system * Signing of informed consent

Exclusion criteria

* Parosmia/phantosmia, hyposmia/anosmia, pre-existing subjective dysgeusia/ageusia * ATCD of sinus or cranial neoplasia * ATCD of sinus or cranial radiotherapy * Neurological or neurodegenerative disease * ATCD of persistent post-viral hyposmia or anosmia (including COVID) (more than 3 months)

Design outcomes

Primary

Measure	Time frame	Description
Passage of olfactory tests:	Day 0	TODA2

Secondary

Measure	Time frame	Description
Identify confounding factors, i.e. factors that can influence the results of the olfactory test	Day 0	gender of patients

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026